HyTherCaP.: Hydralazine: A new therapeutic approach in Castration Resistant Prostate Carcinoma (Q2906475): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: co-financing rate (P837): 85.0 percentage) |
(Changed an Item: Import item from Portugal) |
||||||||||
| Property / budget | Property / budget | ||||||||||
| 239,998.85 Euro
| ||||||||||
| Property / EU contribution | Property / EU contribution | ||||||||||
| 203,999.02 Euro
| ||||||||||
| Property / priority axis | |||||||||||
| Property / priority axis: Strengthening research, technological development and innovation (OT1) / rank | |||||||||||
Normal rank | |||||||||||
| Property / co-financing rate | |||||||||||
85.0 percent
| |||||||||||
| Property / co-financing rate: 85.0 percent / rank | |||||||||||
Normal rank | |||||||||||
Revision as of 11:38, 5 November 2022
Project Q2906475 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | HyTherCaP.: Hydralazine: A new therapeutic approach in Castration Resistant Prostate Carcinoma |
Project Q2906475 in Portugal |
Statements
203,999.02 Euro
0 references
239,998.85 Euro
0 references
85.0 percent
0 references
1 January 2018
0 references
30 June 2021
0 references
INSTITUTO PORTUGUÊS DE ONCOLOGIA DO PORTO FRANCISCO GENTIL - E.P.E.
0 references
Q2997125 (Deleted Item)
0 references
Identifiers
POCI-01-0145-FEDER-029030
0 references